Impression Healthcare (ASX: IHL) has filed a patent for its novel cannabinoid formula known as IHL-216A, which is designed to be used as a neuroprotective agent subsequent to head trauma.
Impression Healthcare (ASX: IHL) is seeking a patent for one of its four novel cannabinoid formulas, which the company's drug discovery team believes will assist with Traumatic Brain Injury (TBI.)
The team argues that the correct administration of the drug following a head injury will help to reduce neuronal cell death and damage, which is a growing concern to many athletes worldwide.
Traumatic Brain Injury, according to IHL, accounts for 10 million deaths/hospitalizations globally each year. Despite the prevalence of TBI, however, there are no existing pharmaceutical agents which have currently been approved to treat it.
Once a Traumatic Brain Injury occurs, IHL argues that their neuroprotective cannabinoid drug should be the first response for medical professionals, in order to reduce neuro-excitation, neuro-inflammation, cerebral blood flow, and cerebral oxygen consumption.
There is a clear need for a post-injury treatment as the personal and societal costs of TBI are enormous.IHL's Chief Medical Officer, Sud Agarwal
"As a neurosurgeon of 16 years standing, I am hopeful that IHL – 216A will be a game-changer in the pharmacological treatment of traumatic brain injury which is a ubiquitous world problem," said Dr Ron Jithoo, specialist neurosurgeon and Impression's medical advisory board member.
The brain injury drug is just one of four drugs in IHL's pipeline, with the others designed for Obstructive sleep apnoea, Gum disease, and Temporomandibular joint disorder.
IHL has its Australian licenses in place, and also has access to robust distribution pathways, thanks to Cannvalate, Australia's largest distribution network of cannabis prescribers.
Should trials be successful for these four novel formulas, IHL will have tapped into four major global markets.
Disclaimer: Past performance is not an indicator of future performance.
& Keep Up to Date
Get the latest pot stock recommendations, cannabis news
and industry updates straight to your inbox!